TUESDAY, Jan. 30, 2018 (HealthDay News) -- For older men with at least one cardiovascular risk factor, treatment with statin and/or pharmacologic blood pressure reduction does not significantly impact erectile function, according to a study published in the January issue of the Canadian Journal of Cardiology.
Philip Joseph, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted a secondary analysis of the Heart Outcomes Prevention Evaluation-3 randomized controlled trial involving 2,153 men age 55 years or older with one or more cardiovascular risk factors. Participants were randomized to rosuvastatin or placebo and to candesartan with hydrochlorothiazide (Cand+HCTZ) or placebo in a 2 × 2 factorial design.
The researchers found that at baseline, the mean erectile function domain of the International Index of Erectile Function (IIEF-EF) score was 23.0. No significant differences were seen in the least square mean change in the IIEF-EF score with rosuvastatin versus placebo (−1.4 versus −1.5; P = 0.74), Cand+HCTZ versus placebo (−1.6 versus −1.3; P = 0.10) or combination therapy versus double placebo (P = 0.35).
"Cholesterol-lowering using a statin, and blood pressure-lowering using Cand+HCTZ, either alone or in combination, do not improve or adversely affect erectile function," the authors write.
Several authors disclosed financial ties to AstraZeneca.
Abstract
Full Text (subscription or payment may be required)
